|
WO2020214753A1
|
|
Combination therapy for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
WO2020176703A1
|
|
Non-invasive biomarkers for use in the treatment of non-alcoholic steatohepatitis and other bile acid-related disorders
|
|
CA3108905A1
|
|
B7-h7-binding agents and methods of use thereof
|
|
WO2020023847A1
|
|
Use of glucagon receptor antagonists with immunotherapeutic agent
|
|
WO2020010077A1
|
|
Bispecific antibodies
|
|
US2019322730A1
|
|
C3-binding agents and methods of use thereof
|
|
WO2019178539A1
|
|
Bispecific antibodies
|
|
US2019169281A1
|
|
ANGPTL8-binding agents and methods of use thereof
|
|
US2018371080A1
|
|
LEAP2 binding agents and compositions thereof
|
|
WO2018195390A1
|
|
Methods of treating gastrointestinal motility -related disorders using variants and fusions of fgf19/fgf21 polypeptides
|
|
PE20191404A1
|
|
GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USING THEM
|
|
US2019307847A1
|
|
Methods for treatment of bile acid-related disorders
|
|
AU2017315459A1
|
|
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
AU2017228489A1
|
|
Compositions and methods for modulating body weight
|
|
PE20190126A1
|
|
BINDING PROTEINS AND METHODS OF USING THEM
|
|
CA3003616A1
|
|
Methods for treatment of bile acid-related disorders
|
|
WO2017019957A2
|
|
Binding proteins and methods of use thereof
|
|
US2018110834A1
|
|
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
CA2961587A1
|
|
Compositions and methods of use for treating metabolic disorders
|
|
SG11201702757YA
|
|
Pharmaceutical compositions comprising peptide variants and methods of use thereof
|
